Levi Garraway (Roche)

Roche claims key win in the $12B ear­ly-stage check­point race

Roche has staked a toe­hold in the race to push check­point ther­a­pies in­to ear­li­er and ear­li­er stages of can­cer.

The Swiss phar­ma an­nounced Mon­day that, in a Phase III tri­al of ear­ly-stage lung can­cer pa­tients, those who re­ceived the PD-1 block­er Tecen­triq lived longer with­out their dis­ease re­turn­ing than pa­tients who re­ceived chemother­a­py did. Known as IM­pow­er010, the study looked at non-small cell lung can­cer pa­tients who had al­ready un­der­gone surgery to re­move their tu­mor.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.